VIKING-MALT
15.3.2021 12:09:13 CET | Business Wire | Press release
Viking Malt, one of the world's leading suppliers of high quality malt products received Platinum Medal in the latest EcoVadis Corporate Social Responsibility (CSR) rating. Platinum is a new medal category for evaluating CSR performance, and this award places Viking Malt in the top 1% of all companies evaluated by EcoVadis and in the top 2% in the category of Manufacture of malt liquors and malt industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210315005366/en/
"Viking Malt’s CSR effort is strongly aligned with our corporate values and business strategy. Practicing CSR helps us become more aware of the impact our business at Viking Malt has on all aspects of society: economic, social and environmental. It also makes it easier for us to build stronger bonds between Viking Malt and our employees, as well as customers and suppliers" – says Annika Wilhelmson, Vice President Innovation, Quality and CSR at Viking Malt. - "Each independent assessment of our sustainability activities is extremely valuable, and these high ratings make us more confident that the path we are following is right, valuable and meaningful."
On Tuesday 9th of March the CEO of Viking Malt, Kasper Madsen, participated in the EcoVadis Sustain 2021 Conference in a panel discussion about “Vision to Value, CEO’s roadmap to Sustainability.” https://tiny.pl/r4z6f
"I really hope our input can help other companies on their sustainability journey. When we were asked about what advice we would give, I would emphasize that every member of the leadership team needs to take ownership of Sustainability – it is part of the way we do business. I see the benefit of being recognized by EcoVadis as it increases our credibility in front of the customers and is valued by them. The positive impact on employee commitment, pride and energy is also not to be underestimated ." – says Kasper Madsen.
EcoVadis is the world’s most trusted provider of business sustainability ratings, intelligence and collaborative performance improvement tools for global supply chains. Backed by a powerful technology platform and a global team of domain experts, EcoVadis’ easy-to-use and actionable sustainability scorecards provide detailed insight into environmental, social and ethical risks across 200 purchasing categories and 160 countries.
About Viking Malt
Viking Malt sells its products globally to the food, beverage and brewing industries. It has 6 production plants in 5 countries: Finland, Sweden, Denmark, Lithuania as well as two plants in Poland. The turnover of the group is appr. 250 million euros and it is the largest malting company in Scandinavia, 5th largest in Europe and 9th in the world. It is the leading company in specialty malt in the global market. Viking Malt Group is owned by Polttimo (62,5 %) and Svenska Lantmännen (37,5 %).
Read our CSR Report: https://www.vikingmalt.com/csr/
More info about the company and products: www.vikingmalt.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210315005366/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 14:00:00 CEST | Press release
A growing wave of unsupported solar systems and rising electricity prices are creating strong demand for Otovo’s energy service platform Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensu
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release
New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 13:00:00 CEST | Press release
Randomized controlled trial will evaluate both symptom progression and underlying biology Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom